A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity.
Acta Biochim Biophys Sin (Shanghai)
; 43(7): 511-8, 2011 Jul.
Article
em En
| MEDLINE
| ID: mdl-21676888
ABSTRACT
Since Mycobacterium bovis bacillus Calmette-Guerin strain (BCG) fails to protect adults from pulmonary tuberculosis (TB), there is an urgent need for developing a new vaccine. In this study, we constructed a novel recombinant BCG strain (rBCG) expressing human granulocyte macrophage colony-stimulating factor (GM-CSF) and the 6 kDa early secretory antigenic target (ESAT6) of Mycobacterium tuberculosis, named rBCGGE (expressing GMCSF-ESAT6 complex), and evaluated the immunogenicity of the construct in BALB/c mice. Our results indicated that the rBCGGE was able to induce higher titer of antibody than the conventional BCG, the rBCGG (expressing GM-CSF) and the rBCGE (expressing ESAT6). Moreover, the rBCGGE also elicited a longer-lasting and stronger Th1 cellular immune responses than the other groups, which was confirmed by the incremental proliferation of splenocytes, the increased percentages of CD4(+) and CD8(+) T cells of spleen, the elevated level of interferon-γ in splenocyte culture after tuberculin-purified protein derivative stimulation, and the increased concentration of GM-CSF in serum. The data presented here suggested the possibility that the recombinant BCGGE might be a good vaccine candidate to TB.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Bactérias
/
Vacina BCG
/
Fator Estimulador de Colônias de Granulócitos e Macrófagos
/
Células Th1
/
Mycobacterium bovis
/
Antígenos de Bactérias
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article